Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.15 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:00 PM 12/14/14 All times are local (Market data is delayed by at least 15 minutes).

neurogesx inc (I8Z) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEUROGESX INC (I8Z)

Related News

No related news articles were found.

neurogesx inc (I8Z) Related Businessweek News

No Related Businessweek News Found

neurogesx inc (I8Z) Details

NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.

35 Employees
Last Reported Date: 03/28/12
Founded in 1998

neurogesx inc (I8Z) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neurogesx inc (I8Z) Key Developments

NeurogesX, Inc. Terminates Employment of its Executive Officers

NeurogesX, Inc. has terminated the employment of Ronald Martell, President and Chief Executive Officer, Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer, and Stephen Peroutka, Executive Vice President and Chief Medical Officer, effective from one business day following the closing the Asset Sales, and such individuals executed releases of the company.

NeurogesX, Inc., Special/Extraordinary Shareholders Meeting, Jun 18, 2013

NeurogesX, Inc., Special/Extraordinary Shareholders Meeting, Jun 18, 2013., at 11:00 Pacific Daylight. Location: Morrison & Foerster LLP, 425 Market Street. Agenda: To consider and vote upon the sale of certain of the Company's assets to Acorda Therapeutics, Inc.; to consider and vote upon one or more adjournments of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1; and to transact such other business as may properly come before the special meeting or any adjournment or postponement.

NeurogesX, Inc. To Be Deleted From OTCBB

NeurogesX, Inc.’s common stock will be deleted from OTC Bulletin Board (OTCBB) effective May 21, 2013, on account of its failure to comply with NASD 6530. The company will be added to NBB.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I8Z:GR €0.15 EUR 0.00

I8Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
POZEN Inc $8.40 USD +0.08
Sunesis Pharmaceuticals Inc $2.69 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation I8Z Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROGESX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at